China Medical System Holdings renewed and expanded its collaboration with Insilico Medicine in a 1.2 billion yuan ($177 million) pact aimed at a mass-market central nervous system indication. The deal taps into existing partnership infrastructure between the two companies, according to the announcement. The collaboration structure signals continued appetite for AI-enabled discovery workflows in CNS, an area where translational and clinical attrition risks have historically been high. For Insilico, the agreement provides additional resources that can help sustain pipeline velocity while supporting IND-enabling and clinical-stage development. For CMS, the expanded relationship keeps it positioned to acquire development leverage through external discovery partners. The headline number and CNS focus will be watched by investors looking for evidence that AI-first approaches can sustain longer-term execution in drug-heavy therapeutic areas.